Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Advanced Drainage Systems Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B), while Advanced Drainage Systems Inc trades at $125.87 (market cap $9.52B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 13.4× Advanced Drainage Systems Inc's market cap, and Advanced Drainage Systems Inc pays a 0.63% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Advanced Drainage Systems Inc for 43 Days on average.
| VRTX | WMS | |
|---|---|---|
Market Cap | $127.55B | $9.52B |
Volume | 1,487,944 | 907,564 |
Sector | Health | Basic Materials |
52-Week High | $557.96 | $175.38 |
52-Week Low | $407.37 | $125.33 |
Typical Hold Time | 120 Days | 43 Days |
Enterprise Value | $121.68B | $11.12B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
WMS (Advanced Drainage Systems) trades at $124.92, down 0.92% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin and 24.9% ROE. Recent news includes the release of its 2026 Sustainability Report and a declared dividend of $0.20 per share payable in September 2026.
The outlook is supported by consistent earnings beats and analyst consensus pointing to significant upside with a $188.70 price target. However, a projected negative net cash flow of -$473M for 2026 and bearish technical indicators present near-term risks. Investor sentiment is mixed amid institutional buying and selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
